Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)

The development of gastrointestinal stromal tumors (GISTs) is largely driven by mutations in the KIT and PDGFRα genes. Imatinib mesylate is an oral small molecular tyrosine kinase inhibitor that mainly targets abl, c-KIT, and PDGFRα. Imatinib achieves disease control in approximately 70%–85% of pati...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Onco Targets Ther
Egile Nagusiak: Spitaleri, Gianluca, Biffi, Roberto, Barberis, Massimo, Fumagalli, Caterina, Toffalorio, Francesca, Catania, Chiara, Noberasco, Cristina, Lazzari, Chiara, de Marinis, Filippo, De Pas, Tommaso
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Dove Medical Press 2015
Gaiak:
Case Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4548749/
https://ncbi.nlm.nih.gov/pubmed/26316776
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S81558
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak